Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and AbbVie (ABBV)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jazz Pharmaceuticals (JAZZ – Research Report) and AbbVie (ABBV – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jazz Pharmaceuticals (JAZZ)
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $235.00. The company’s shares closed last Thursday at $171.16.
According to TipRanks.com, Bansal is a 5-star analyst with an average return of
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $219.54, which is a 28.7% upside from current levels. In a report issued on January 9, RBC Capital also maintained a Buy rating on the stock with a $191.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
AbbVie (ABBV)
In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on AbbVie, with a price target of $233.00. The company’s shares closed last Thursday at $216.75, close to its 52-week high of $218.66.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $254.06, representing a 14.2% upside. In a report issued on January 8, Wolfe Research also downgraded the stock to Hold.
